63 patents
Page 2 of 4
Utility
Methods for treating lysosomal acid lipase deficiency in patients
2 Aug 22
The present invention provides methods of treating LAL deficiency comprising administering to a mammal a therapeutically effective amount of lysosomal acid lipase with an effective dosage frequency.
Anthony Quinn
Filed: 14 Nov 18
Utility
High concentration anti-C5 antibody formulations
21 Jun 22
The present disclosure relates to stable aqueous solutions comprising a high concentration of an anti-C5 antibody (e.g., ravulizumab) and methods for preparing the solutions.
Stephan Ortiz, Jillian Gentile, Leena Philominathan, Eric Routhier, Bruce Mason
Filed: 27 Jul 18
Utility
9d8hv5wxl9xw6dad0b6ecpo3d ocasbkysxq01povw3sy
7 Jun 22
A method for producing a recombinant polypeptide, comprising: (a) providing a 100 L to 25,000 L fed-batch bioreactor comprising (i) cells capable of expressing the recombinant polypeptide asfotase alfa (SEQ ID NO: 1), and (ii) a culture medium suitable for conducting such expression, the culture medium comprising about 25 μM to about 300 μM zinc; (b) culturing the cells under conditions suitable to express the recombinant asfotase alfa wherein the pH of the culture medium is about 6.7 to about 7.1, and wherein zinc is added into said culture medium such that the zinc concentration in the culture medium is maintained at a concentration of about 25 μM to about 300 μM of zinc.
Pratik Jaluria, Siguang Sui
Filed: 16 Aug 16
Utility
fo9ih7e0aw3wzwg28ggud8cfcawtwy2ef9k9zu3t5ad8n85ljss4czb
24 May 22
Anjali Pandey, Arvinder Sran, Ying Chen, Daniele Poggiali, Tiziano Fumagalli
Filed: 21 Oct 20
Utility
fznqimzc ucsernlutujjow6qii8gyyiqwbxds2xqsrlj
8 Mar 22
Compositions and methods for treating lymphoma, in particular, T-cell lymphoma and follicular lymphoma, in a human patient are provided.
Gregory Coffey, Matthew Birrell, Pamela B. Conley, John T. Curnutte, Anjali Pandey, Andrew Steele, Glenn Michelson
Filed: 3 May 19
Utility
fudukunkqawyc3r5uu6ki5l0qio9w7pn2w0
15 Feb 22
A bone delivery conjugate having a structure selected from the group consisting of: A) X-Dn-Y-protein-Z; and B) Z-protein-Y-Dn-X, wherein X is absent or is an amino acid sequence of at least one amino acid; Y is absent or is an amino acid sequence of at least one amino acid; Z is absent or is an amino acid sequence of at least one amino acid; and Dn is a poly aspartate wherein n=10 to 16.
Philippe Crine, Guy Boileau, Isabelle Lemire, Thomas P. Loisel
Filed: 28 Dec 18
Utility
izujbubv2naha3tvdp0wcpdgb7nzy9t e8o2dk2bhx7g3bxht2eqzkasm
8 Feb 22
This invention provides, inter alia, a complement-inhibitor-based treatment plan coupled with a risk evaluation and management strategy (“REMS”) and a safety support program (“SSP”) for reinforcing the REMS.
Leonard Bell, Camille Bedrosian
Filed: 6 Jun 17
Utility
eh77mzattow6fk9wky9n0bz3ou jvyj2gpqflnizcmk1w227tr28w8hj
1 Feb 22
Compositions and methods relating to potentially pathogenic mutations in the nucleotide sequence of a human LIPA gene.
Andrew Hutchinson, John V. W. Reynders, Guillermo del Angel, Nina Jain, Christen D. Forbes, Xiao-Qin Ren, Barbara Burton
Filed: 16 Jun 17
Utility
2bzpleiisw9iqvsdimsjnia8nlmuydvzk m3xq9tzckz
25 Jan 22
A method of treating a human having a condition or disease related to a bone defect characterized by at least one of: increased level of an alkaline phosphatase ligand, particularly PPi, PLP, or PEA; and decreased alkaline phosphatase activity, compared to a human without said condition or disease, comprising administering to the human a therapeutically effective amount of a polypeptide comprising the amino acid sequence of SEQ ID NO: 1, wherein the polypeptide is administered through at least one subcutaneous injection to the human in a frequency of fewer than three times each week.
Rajendra Pradhan, Xiang Gao
Filed: 27 Sep 16
Utility
b0qzndhy76io09rme5rp6mx7lgi0oz3u9zjnx1lek1
18 Jan 22
The disclosure features methods for treating hypophosphatasia (HPP) in a patient (e.g., an adult having HPP, such as an adult having pediatric-onset HPP, or an adolescent having HPP) exhibiting decreased pyrophosphate (PPi) or pyridoxal 5′-phosphate (PLP) concentrations in, e.g., a plasma sample, physical impairments, or decreased walking ability by administering a soluble alkaline phosphatase (sALP) to the patient.
Scott Edward Moseley, Andrew E. Denker, Wei-Jian Pan
Filed: 29 Mar 18
Utility
1ka8eaicjmz5xktjxu6umix2emvrwk7gff
18 Jan 22
The present disclosure provides a method of treating seizure in a subject having aberrant alkaline phosphatase activities, comprising administering a therapeutically effective amount of at least one recombinant alkaline phosphatase to the subject.
Andre Marozsan, Denise Devore, Susan Liu-Chen
Filed: 18 Oct 19
Utility
5s45o1ty99pntd4od8uomk8ml5wlkxbcxo508doiljh
21 Dec 21
The present disclosure relates to, inter alia, a method of treating age-related macular degeneration (AMD) in a patient, comprising administering an effective amount of a C5 inhibitor or a C5a inhibitor.
Yi Wang, Barbel Rohrer
Filed: 6 Oct 16
Utility
e2dw2k3bwn9egfshjprekdcvvo3znig vko7seqk7
14 Dec 21
Described herein are isolated monovalent antibodies or antibody fragments thereof that bind human properdin.
Douglas L. Sheridan, Paul P. Tamburini, Taneisha Ann-Tanara Mack, Walter C. Voegtli
Filed: 30 Jan 18
Utility
ctu0bsyln2ooyz5nia0wkn9eqtd7g5bafyn0bn6qta4r07cs
30 Nov 21
The disclosure features methods for treating or ameliorating at least one symptom of a subject having or being prone to a muscle weakness disease, comprising administering to said subject a therapeutically effective amount of at least one recombinant polypeptide having alkaline phosphatase activity.
Andre Marozsan
Filed: 31 Mar 17
Utility
267cv8amjrgkcea9q 8yd0dvfvzgiuoabt
26 Oct 21
The present invention is related a method of purifying a heterologous protein from an egg white.
Liang Chen, Markley C. Leavitt, Michael Titus, Stephen Palmieri
Filed: 22 Aug 17
Utility
fxihss5qbimgeog17im932nsrf08xalkbs0k94b4
14 Sep 21
The disclosure features methods for treating tracheobronchomalacia (TBM) in a patient having hypophosphatasia (HPP), such as an infant, by administering a soluble alkaline phosphatase (sALP) to the patient.
Howard M. Saal
Filed: 18 Aug 17
Utility
3bgejfgyen76pp7hg4irv1ifjllfq47hsnlaircmwwbkczo7u0mhi8
7 Sep 21
The disclosure relates to methods for detecting PNH Type II cell populations in biological samples as well as methods for determining whether a patient is at an increased risk for developing thrombocytopenia or thrombosis based on the percentage of PNH Type II cells in the patient's blood.
Mayur Movalia, Andrea Illingworth, Susan Faas McKnight, Russell P. Rother
Filed: 9 Oct 18
Utility
lc6yr5aq srf9kb7hx5kicy989hsgv0b
7 Sep 21
Provided herein are methods for simultaneously detecting and quantifying antibodies which bind to the same target and have high sequence identity, such as eculizumab and ALXN1210, present together or alone in a biological sample.
Meng Chen, Ryan Pelto
Filed: 28 Mar 18
Utility
9uiitwtkg4ip8iso9ejmv1kua5yilnx0gb1esgiaixu kui2a79ym
31 Aug 21
Provided herein are methods of replicating a large scale eculizumab production cell culture in a small scale culture.
Hunter F. Malanson, Pratik Jaluria
Filed: 10 Dec 19
Utility
8knv4utl4gyvxl 826t209pjgoyyf
20 Jul 21
The disclosure features methods for treating hypophosphatasia (HPP) in a patient (e.g., a child having HPP) exhibiting physical impairments, disability in activities of daily living (ADL), pain, and/or delayed motor development by administering a soluble alkaline phosphatase (sALP) to the patient.
Kenji Fujita, Dawn Phillips
Filed: 1 Sep 16